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Abstract
T cell lymphoblastic leukemia (T-ALL) is known to be associated with chromosomal abnormalities that lead to aberrant
expression of a number of transcription factors such as TAL1, which dimerizes with basic helix-loop-helix (bHLH) E proteins
and inhibits their function. Activated Notch receptors also efficiently induce T cell leukemogenesis in mouse models.
Interestingly, gain-of-function mutations or cryptic transcription initiation of the Notch1 gene have been frequently found
in both human and mouse T-ALL. However, the correlations between these alterations and overall Notch activities or
leukemogenesis have not been thoroughly evaluated. Therefore, we made use of our collection of T cell lymphomas
developed in transgenic mice expressing Id1, which like TAL1, inhibits E protein function. By comparing expression levels of
Notch target genes in Id1-expressing tumors to those in tumors induced by a constitutively active form of Notch1, N1C, we
were able to assess the overall activities of Notch pathways and conclude that the majority of Id1-expressing tumors had
elevated Notch function to a varying degree. However, 26% of the Id1-expressing tumors had no evidence of enhanced
Notch activation, but that did not delay the onset of tumorigenesis. Furthermore, we examined the genetic or epigenetic
alterations thought to contribute to ligand-independent activation or protein stabilization of Notch1 and found that some
of the Id1-expressing tumors acquired these changes, but they are not uniformly associated with elevated Notch activities in
Id1 tumor samples. In contrast, N1C-expressing tumors do not harbor any PEST domain mutations nor exhibit intragenic
transcription initiation. Taken together, it appears that Notch activation provides Id1-expressing tumor cells with selective
advantages in growth and survival. However, this may not be absolutely essential for lymphomagenesis in Id1 transgenic
mice and additional factors could also cooperate with Id1 to induce T cell lymphoma. Therefore, a broad approach is
necessary in designing T-ALL therapy.
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Introduction
T cell lymphoblastic leukemia (T-ALL) is often associated with
chromosomal translocations and alterations that lead to dysregu-
lation of the expression of a range of transcription factors or
alteration of their functions [1,2]. For example, aberrant
expression of the TAL1 gene is found in more than half of the
childhood T-ALL cases, which is frequently due to the t (1;14)
translocation or intergenic deletions upstream of the TAL1 gene
[1,2]. TAL1 is a basic helix-loop-helix (bHLH) protein and
dimerizes with bHLH E proteins (represented by E2A) to bind to
DNA [3]. While complexes containing TAL1, E2A, LMO2,
GATA1 and LDB1 are capable of activating transcription of genes
involved in erythroid differentiation [4], heterodimers of TAL1
and E2A exhibit diminished transcriptional activity in comparison
to E2A homodimers [5,6]. This raises the possibility that TAL1,
when expressed out of its natural contexts, acts as a dominant-
negative inhibitor to predispose T cells to leukemogenesis [7–9].
This notion is supported by observations that ablation of the
E2A gene leads to the formation of T cell lymphoma in mice
[10,11]. Consistently, the oncogenic potential of TAL1 has been
shown to be independent of its transcriptional and DNA binding
activity but requires the HLH dimerization domain [8].
Furthermore, we and others have shown that expression of the
Id proteins diminishes the DNA binding activity of E proteins,
blocks T cell development and causes T cell lymphomas in
transgenic mice at high frequencies and penetrance [12–15].
Therefore, E proteins have been regarded as tumor suppressors, at
least in the T lymphoid lineage.
Constitutive activation of Notch receptors have also been shown
to have potent oncogenic effects on T cells, inducing T cell
leukemia in less than two months [16,17]. Unlike the TAL1 gene,
chromosomal translocation events that cause Notch activation are
rarely found in human T-ALL patients [18]. However, gain-of-
function point mutations of the Notch1 gene have been found in a
large fraction of human T-ALL [19–21]. Likewise, mutations have
also been detected in T cell lymphomas developed in mouse
models lacking the function of transcription factors such as Ikaros
and E2A [15,22–24]. Point mutations in the heterodimerization
(HD) domain and the PEST sequence of the Notch1 gene render
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proteasome-mediated degradation, respectively [19]. The HD
domain mutations have been shown to possess more potent
transforming activity than mutations in the PEST sequence [25].
While the mutations in the HD domain are commonly found in
human T-ALL, these alterations are relative rare in mouse T-ALL
[21]. Instead, several mechanisms involving cryptic initiation of
Notch1 transcription have recently been shown to produce
truncated Notch1 proteins. They include alternative promoter
usage resulted from 59 deletion or RAG-mediated recombination
and intragenic initiation of Notch1 transcription at regions
between exons 25 and 29 [26–28]. These alterations could have
similar effects as the HD domain mutations found in human T-
ALL and result in the ligand-independent activation of Notch1.
Given the potent oncogenic effects of Notch signaling in T-ALL
animal models, spotlights have been focused on Notch when
considering therapeutic strategies. Inhibitors of c-secretases have
been shown to elicit cell cycle exit in T-ALL cells and induce
apoptosis [29–31]. However, a clinical trial with this family of
inhibitors showed no objective clinical responses and due to the
intestinal toxicity of Notch inhibition, the trial was terminated
[32]. Furthermore, the majority of the data from the studies
correlating the incidence of Notch mutations and clinical
outcomes of T-ALL indicate that activating mutations of the
Notch1 gene or inactivating mutations of the Fbxw7 gene, which
encodes a ubiquitin ligase instrumental for Notch degradation, are
associated with a favorable prognosis to conventional therapies
[33–36]. These observations highlight the need for a better
understanding of the contribution of Notch activation in the
pathogenesis of T-ALL.
Since Notch activation is found to overlap with other genetic
alterations in most of the T-ALL cases [1], it is important to ask
whether Notch signaling is the critical initiating factor of T cell
leukemogenesis while abnormalities of various transcription factors
enable Notch activation. Conversely, it is possible that gain-of-
function mutations of the Notch signaling pathway accumulates
under selective pressure for the survival and proliferation of
leukemic cells which harbor other oncogenic factors or lack certain
tumor suppressors. It is also important to note that despite the
observations of these genetic or epigenetic alterations of the
Notch1 gene, their correlations with Notch activities in leukemic
cells remain to be carefully determined.
Figure 2. Survival curves of Id1 and N1C-expressing mice. Id1
transgenic mice and ROSA26-stop-N1C/lck-Cre mice were monitored for
signs to tumor growth judging by hunched back and labored
breathing. Median survival and statistics were determined using the
Prism software and Log-rank (Mantel-Cox) Test.
doi:10.1371/journal.pone.0032944.g002
Figure 1. Characterization of N1C-expressing T cell lymphoma. Single cell suspensions from normal and tumor tissues were analyzed using
FACS. The percentage of GFP was determined after excluding PI positive cells and by using wild type thymocytes as a negative control. Thymocytes
from a 22 day-old ROSA26-stop-N1C/lck-Cre mouse were used as a pre-tumor control. Percentages of cells of indicated surface phenotypes are label
within the plots. The designations of the tumor samples on top of the plots correspond to the identifications of these tumors used throughout the
study.
doi:10.1371/journal.pone.0032944.g001
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between Notch activation and loss of E2A function. Although E
proteins have been shown to be involved in the transcriptional
activation of the Notch1 gene [37], the situations in T cell
lymphomas resulted from E protein deficiency may be entirely
different. Previous data on gain-of-function Notch mutations have
been mostly obtained using E2A deficient T-ALL cell lines and in
TAL1 transgenic tumors [24,38,39]. Here, we made use of our
collections of T cell lymphomas developed in mice expressing Id1
or Notch1 intracellular domain (N1C). By comparing levels of
best-known Notch target genes and incidences of gain-of-function
events in Id1 and N1C-expressing tumor samples, we conclude
that a large fraction of Id1-expressing tumors exhibit evidence of
significant Notch activation. However, a substantial fraction of
tumors do not show elevated expression of Notch target genes,
suggesting that Notch signaling is dispensable for T cell
lymphomagenesis. Furthermore, intragenic transcription initiation
occurs in Id1 but not N1C-expressing tumors, and it correlates
with increased Notch activities to some extent. Yet, exceptions
have been found in several cases where cryptic starts of
transcription do not result in Notch activation. Findings from
these studies suggest that although multiple genetic and epigenetic
alterations that lead to Notch activation accumulate through
selective pressure for growth or survival of Id1-expressing
lymphoma cells, tumorigenesis can occur independently of Notch
activities. Therefore, simple Notch targeting therapy might not be
sufficient for eradicating T-ALL.
Results
Activation of Notch signaling pathways in Id1 transgenic
T cell lymphomas
We have previously shown that transgenic expression of Id1
under the control of the lck proximal promoter leads to the
formation of T cell lymphoma in the thymus with high penetrance
and a median survival of 21.5 weeks [15]. We have archived a
series of these tumor samples and analyzed the CD4 and CD8
expression profile of each tumor. Since the tumors are usually 10–
50 times the size of a normal thymus, the majority of the cells
collected are likely derived from tumor cells. FACS analyses
usually showed a predominant population of cells (data not
shown). In addition, we also have a collection of tumors harvested
from ROSA26-Stop-N1C mice crossed with lck-Cre transgenic
mice. Like the Id1 tumors, NIC-expressing tumors are also large in
size and almost invariably metastasize to lymph nodes, liver or/
and kidney. Representative FACS profiles of these tumors are
shown in Fig. 1. NIC-expressing tumors exhibit different surface
phenotypes with regard to CD4, CD8, CD25 and TCRb
expression. Since expression of N1C is turned on by Cre
recombinase driven by the lck promoter, which was also used to
control Id1 expression in the transgenic mice, we were interested
in comparing the tumorigenic potential between Id1 and N1C. In
contrast to the median survival of 21.5 weeks determined for Id1
mice, that of N1C-expressing mice was 10 weeks, indicating a
much more potent oncogenic effect of N1C than Id1 (Fig. 2).
To compare the extent of Notch activation in Id1 and N1C-
expressing tumors, we randomly selected a set of samples of each
genotype and examined expression levels of Notch1 as well as
representative Notch downstream target genes including Hes1,
Deltex1, c-myc and Notch3 [40]. The 23 Id1-expressing tumors
are designated as IT1 to 23, while the 11 N1C-expressing tumors
are dubbed NT1 to 11. Two thymus samples without any obvious
signs of tumor growth from 3-week old N1C-expressing mice were
also included as pre-tumor controls, called NP1 and NP2. Real-
time PCR analyses were performed and levels of expression were
normalized to a reference control generated from total wild type
thymocytes so that the relative levels of each transcript expressed
in all samples are comparable. In Fig. 3, data from Id1 and N1C-
expressing tumors are arranged in ascending orders with regard to
endogenous Notch1 expression detected by PCR amplification
with primers binding to the 39 region of the transcript, and the
samples are named accordingly.
Expression of human N1C in pre-tumor thymocytes from the
ROSA26 locus activated transcription of its known downstream
targets such as endogenous Notch1, Hes1, Deltex1, c-myc and
Notch3 (Fig. 3). Consistently, N1C-expressing tumors showed
uniformly high levels of expression of Notch targets, proportional
to the levels of human N1C (Fig. 4). One exception is the
uncharacteristically lower level of c-myc expression in NT7 despite
higher levels of Notch1 and 3 in this sample.
Among the Id1-expressing tumors, the 23 samples can be
divided into three groups, groups A to C, based on Notch1
expression (Fig. 3). Group C includes sample IT20-23, which
expressed comparable or higher levels of endogenous Notch1 and
Hes1 relative to N1C-expressing tumors (Group D). Their levels of
Deltex1, c-myc and Notch3 were similar to those of N1C tumors.
Figure 3. Quantitative analyses of expression of Notch target genes in Id1 and N1C-expressing tumors and normal tissues. Total RNA
was isolated from archived Id1 and N1C tumor samples or fresh thymocytes. Real-time PCR analyses were performed with primers for indicated
genes. Levels of transcripts were normalized against that of b-actin by calculating DCT. Expression levels relative to that of a control generated from
cDNA of wild type thymocytes were determined by using the 2
2DDCT formula. Data shows the average with standard deviations obtained from
triplicates, which was calculated as described [50]. Throughout the manuscript, Id1-expressing tumors are designated as ‘‘IT’’ (red) whereas N1C-
expressing pre-tumor and tumor samples are called ‘‘NP’’ (light blue) and ‘‘NT’’ (blue), respectively. Statistical analyses were performed using
Student’s t tests among groups A to D as marked on top of the first bar graph. p values are presented in a table shown at the bottom. Values above
0.05 are highlighted in light pink.
doi:10.1371/journal.pone.0032944.g003
Figure 4. Expression of the transgenes. Levels of Id1 and human
N1C transcripts were determined as described for Figure 3.
doi:10.1371/journal.pone.0032944.g004
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of Notch1, Deltex1 and Notch3 compared to Group C and D (p
values are less than 0.002 from the Student’s t test) whereas the
difference for Hes1 levels was less remarkable. There are also
inconsistencies among different Notch targets. For example, IT9
had a low level of Hes1 but high levels of Deltex1 and c-myc. On
the other hand, IT18 generated extremely high levels of c-myc
whereas those of Hes1, Deltex1 and Notch3 were rather low
compared to other samples in this group. Nonetheless, Groups B
and C, which constitutes 74% of the samples analyzed, exhibited
evidence of elevated Notch signaling as indicated by the expression
of various Notch target genes.
However, Group A, which represents the remainder 26% of the
samples (IT1-6), showed extremely low levels of Notch1, Deltex1
and Nocth3 expression. Hes1 levels were also very low except for
two samples, IT1 and 5 (Fig. 3). Thus, it appears that Notch
activity is minimal in these 6 tumors. Surprisingly, c-myc levels in
these tumors were comparable to samples in other groups. In fact,
no statistical significance was found in the differences of c-myc
expression among any of the groups, thus raising the question if
the c-myc gene is activated independently of Notch signaling
(Fig. 3).
As controls, we measured levels of transgene expression in both
Id1 and N1C tumors. Very high levels of Id1 expression were
detected in all but 2 tumors whereas N1C expression was relatively
uniform in all tumors (Fig. 4).
Intragenic transcription initiation of the Notch1 gene
contributes to Notch activation in Id1 tumors
To understand how Notch activities are elevated in these tumor
cells, we examined several mechanisms known to aberrantly
Figure 5. Examination of intragenic transcription initiation of the Notch1 gene. Real-time PCR analyses were carried out using Id1 (A) and
N1C (B) samples described in Fig. 3. Primer pairs amplifying the 59 and 39 regions of Notch1 bind to sequences encoded by exons 5 to 6 and 33 to 34,
respectively. Data for 39 Notch1 is the same as those shown in Fig. 3. The ratio of levels of 39 to 59 Notch1 in each sample was compared to the
average levels in wild type mice obtained from 6 FVB/N (A) and 4 C57BL/6 (B) mice, respectively. (C) PCR amplification using primers binding to intron
27 and exon 33 for an intragenic transcript designated as exon 27b-exon 33. Amplification of b-actin serves as a quality control of cDNA. Products
were analyzed on agarose gel electrophoresis and inversed photograph is shown. NTC, no template control.
doi:10.1371/journal.pone.0032944.g005
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intragenic transcription initiation occurs in the region spanning
exon 25 to exon 29 of the Notch1 gene as a result of the loss of
Ikaros function or 59-end deletion of the Notch1 gene [26–28].
The resulting cryptic transcripts encode truncated Notch1
receptors that are capable of ligand-independent proteolytic
cleavages, generating intracellular domains of Notch1 capable of
transcriptionally activating its downstream targets. To test if these
events occurred in Id1 transgenic T cell lymphomas, we
determined levels of Notch1 transcripts by using PCR primers
specific for exons 5–6 and exons 33–34 to amplify Notch1
transcripts via the 59 and 39 ends, respectively (Fig. 5A). The levels
of the 59 and 39 transcripts in total thymocytes of 6 individual wild
type mice were also measured. As reported previously [26–28],
wild type thymocytes only transcribe full-length Notch1 mRNA,
and therefore the average ratio of the level of 39 transcripts over
that of 59 transcript in wild type thymocytes was set as 1.
Subsequently, the ratio in each tumor sample was determined and
normalized against the wild type value. This result has been
verified by using additional pairs of PCR primers binding to 59
and 39 ends of the transcript, respectively (data not shown). We
considered a ratio of 1.5 to be highly significant based on the
assumption that one of the two Notch1 alleles produces the cryptic
transcripts at the same level as the full-length species. By this
criterion, 9 out of the 23 tumors appeared to generate the
truncated message and hence the activated form of Notch1
protein. In contrast, T cell lymphomas developed in N1C-
expressing mice did not show any sign of cryptic intragenic
transcription initiation by the same measurements (Fig. 5B).
To further validate this finding, we PCR-amplified an
intragenic transcript initiated in intron 27 by using a specific 59
primer that does not recognize conventional transcripts [26]. As
shown in Fig. 5C, no product was obtained using cDNA of wild
type thymocytes as a template. However, a product of expected
size was detected in IT20-22 but not in other IT samples or NT
samples (Fig. 5C, data not shown). This product was sequenced
and found to match the sequence between intron 27 and exon 33.
Therefore, it appears that 3 of the 9 samples thought to harbor
intragenic transcripts based on the 39 to 59 ratio actually initiated
transcription from a cryptic promoter in intron 27. Other samples
with high 39 to 59 ratios might have started transcription in other
locations between exons 25 and 29, for which PCR detection
methods are currently not available.
Alternative promoter usage at the 59 end of the Notch1
gene is activated by Notch signaling
A second mechanism has been suggested by the discovery of
alternative promoters used to initiate transcription upstream of the
conventional exon1 (E1c), thus creating an alternative exon 1,
named E1a, which is then joined with exon 3 by RNA splicing
[28]. This transcript codes for a product which can also be
activated in a ligand-independent manner. Loss of Ikaros function
is thought to correlate with this alternative promoter usage.
Therefore, we determined the levels of Notch1 transcripts
containing the E1a or E1c exon (Fig. 6). In Id1-expressing tumors,
several samples clearly expressed 2-fold higher levels of the E1a
transcript compared to the average level of wild type controls
(Fig. 6A). Using the Pearson test (x
2), we detected a significant
correlation between the levels of E1a and Notch1 transcripts in
this group of samples. However, no correlation was found with the
expression levels of other Notch target genes.
Consistently, the levels of the E1a transcript were significantly
higher in all of the N1C-expressing tumor samples except for NT1
(Fig. 6B). In the pre-tumor samples, the levels of the E1a transcript
were also very high. These observations raised the possibility that
Notch signaling itself stimulates the transcription initiation at the
alternative promoter and generates E1a-containing transcripts.
Therefore, the increased levels of E1a transcripts in some of the
Id1-expressing tumors could be due to high levels of Notch
function in the tumors cells but expression of E1a transcripts could
perpetually reinforce Notch signaling. However, it is noted that
Figure 6. Examination of alternative promoter usage at the 59 end of the Notch1 gene. Transcripts containing the alternative (E1a) and
conventional (E1c) exon 1 were amplified using specific primers designed by Gomez-del Arco et al. The levels in each pre-tumor or tumor samples
were compared to the average levels in wild type mice obtained from 6 FVB/N (A) and 4 C57BL/6 (B) mice, respectively.
doi:10.1371/journal.pone.0032944.g006
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this transcript, suggesting that additional levels of control are at
play.
Point mutations accumulate in Id1 but not N1C-
expressing tumors
It is also well known that point mutations in the Notch1 gene
result in mutant proteins with enhanced activities. Mutations in
the heterodimerization domain (HD), which occur more frequent-
ly in human T-ALL, expose the protease cleavage sites and cause
ligand-independent release of the intracellular domain [41]. On
the other hand, missense or frame-shift mutations in the PEST
domain, more commonly found in mouse T cell lymphomas,
stabilize Notch1 proteins by preventing ubiquitin-mediated
degradation. Sequence analyses of the HD and PEST regions in
Notch1 transcripts expressed in Id1 tumor samples revealed such
mutations at frequencies of 17% and 60% respectively (Fig. 7). In
contrast, none of the N1C tumors harbor any mutations in the
PEST region and it would be unlikely that they would have
mutated HD domain which is known to be rare in mouse T cell
tumors (Fig. 7). These results suggest that the gain-of-function
mutations in the Notch1 gene provides tumor cells with selective
advantage despite the presence of other Notch-activating mech-
anisms as described in previous sections. However, the N1C
tumors have no need for these mutations as they already express
high levels of a constitutively active form of Notch1.
Id1 expression in normal thymocytes does not cause
cryptic transcription initiation of the Notch1 gene
Considering that 40% of the Id1 tumors exhibited intragenic
initiation of transcription and 35% of them showed elevated
expression of E1a containing transcripts, we were interested in
determining if Id1 expression had any direct consequence in these
cryptic transcriptional events. Wild type and pre-malignant Id1
transgenic thymocytes were fractionated by cell sorting based on
their developmental profiles, namely CD4 and CD8 double
negative (DN), double positive (DP) and single positive (SP) stages.
Within the DN population, the cells were further divided into
DN1 to DN4 subsets based on CD44 and CD25 surface
phenotypes. Immature CD8 single positive cells, which represent
cells at the DN to DP transition, were identified based on low
levels of TCRb expression. Consistent with previous observations,
endogenous Notch1 expression detected by either 59 or 39 primer
sets was the highest at DN2 and DN3 stages [42]. Id1 expression
inhibited Notch1 expression which is expected as E2A proteins are
thought to be activators of Notch1 transcription [37]. However,
comparison between the levels of Notch1 detected by 39 primer
pair to those with 59 primer pair did not reveal any discrepancy in
either wild type or Id1 transgenic thymocytes (Fig. 8A), as detected
in Id1 tumors. These results thus suggest that inhibition of E2A
function by Id1 does not by itself induce intragenic transcription
initiation.
Likewise, examination of E1a and E1c containing transcripts
showed high levels of expression at DN2 and DN3 stages in wild
type mice. Id1 transgenic mice produced much lower levels of
both types of transcripts, suggesting that Id1 does not specifically
initiate Notch1 transcription at the promoter near E1a (Fig. 8B).
More significantly, E1a transcripts were more dramatically up-
regulated at the DN2 and DN3 stages of wild type thymocytes
than the E1c transcripts (e.g. 133 fold versus 23 fold in DN3 cells).
These results may be interpreted to mean that transcription from
the alternative promoter that gives rise to E1a-containing
transcripts is a normal event which occurs as T cell progenitors
develop in the thymus and at the stages when Notch function is
critically required. Production of Notch1 proteins which can be
activated in a ligand-independent manner would be able to better
meet the demand for Notch function. Furthermore, it is interesting
to note that Id1 expression had a more profound inhibitory effect
on expression of the E1a transcript than the E1c transcript, which
might provide a clue as to how Id1 effectively suppresses T cell
differentiation [12,42,43].
Reduction in Ikaros expression in Id1 tumors
Since Ikaros is implicated in the suppression of these cryptic
transcriptional events, we determined the levels of Ikaros in Id1-
expressing tumors in comparison to those in N1C-expressing
tumors [26,28]. In 60% of Id1 tumors (18 samples), Ikaros
expression was reduced to less than 70% of the wild type level
(Fig. 9A). However, none of the N1C tumors exhibited decreased
Ikaros expression and some had up to 2-fold increases (Fig. 9B).
These data suggest that diminution of Ikaros expression offers
selective advantage in Id1 tumor cell survival or growth, probably
by allowing the usage of alternative promoters in the Notch1 locus.
While the majority of the samples thought to produce intragenic (9
Figure 7. Examination of point mutations in Id1 and N1C-
expressing tumors. The heterodimerization domain and the PEST
domain of the Notch1 coding sequence were PCR amplified separately
and the products were sequenced. Bar graphs show the numbers of
tumors with wild type (grey) or mutant (black) genotypes. The
percentage of each genotype is shown within the bars. The natures
of the mutations are summarized in Fig. 10.
doi:10.1371/journal.pone.0032944.g007
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of Ikaros, there were a few exceptions, namely, two tumors with
normal levels of Ikaros generated E1a transcripts and three tumors
with low levels of Ikaros did not have these cryptic transcripts.
Discussion
In this report, we have examined Notch activities in a series of T
cell lymphomas developed in Id1 transgenic mice in comparison to
those in tumors from ROSA26-N1C/lck-Cre mice. Several
Notch-activating mechanisms including cryptic transcription
initiation at the 59 end or intragenic regions and point mutations
have also been analyzed. By putting these pieces of information
together as illustrated in Fig. 10, we were able to assess the
contribution of aberrant Notch activation to T cell lymphoma-
genesis in the context of loss of E protein function. Furthermore,
we were able to evaluate the contribution of different mechanisms
that are thought to cause Notch activation to the overall Notch
activity in tumor cells and a number of lessons have been learned.
First, while the majority of Id1 tumors showed evidence of
Notch activation based on up-regulation of the expression of
Notch1 and to a varying degree, its downstream targets, 26% of
the tumors did not appear to have significantly elevated Notch
activities. This suggests that other oncogenic factors beside Notch
are able to cooperate with loss of E2A function in tumorigenesis.
Second, although levels of Hes1, Deltex1 and Notch3 are
generally in parallel with that of Notch1 except in a few cases,
the level of c-myc did not correlate with Notch1 levels based on
statistical analyses. The level of c-myc fluctuated within less than
10 folds compared to wild type control regardless the levels of
Notch activity, suggesting that Notch-independent activation of
the c-myc gene also occurs. One extreme example is sample IT18,
which produced the highest level of c-myc but very low levels of
Hes1, Deltex1 and Notch3.
With regard to the cryptic transcriptional events, their effects on
the overall Notch activity in Id1 tumors are also variable.
Intragenic transcription seemed to be associated with high Notch
activities in samples IT20-22. However, it did not lead to high
levels of Notch activities in IT5, 7 and 9. Alternative promoter
usage leads to production of E1a-containing transcripts, which
encodes the protein also capable of ligand-independent activation.
Levels of this transcript appeared to be higher in a fraction of
tumors that have more abundant Notch activities, namely IT14-
23, which is consistent with the observation that ectopically or
endogenously activating Notch signaling results in an elevation in
the levels of this transcript (Fig. 6 and 8). However, not all Id1
tumors with high levels of Notch activities expressed the E1a-
containing transcript, suggesting the existence of additional layers
of control. On the other hand, most of the N1C tumors
transcribed high levels of the E1a message. Combined with the
Figure 8. Analyses of cryptic transcriptional events in normal thymocytes. Thymocytes from one-month-old wild type and Id1 transgenic
mice were sorted based on their developmental stages as described in Materials and Methods. Levels of indicated Notch1 transcripts were
determined as described in Figures 5 and 6. Data are presented relative to the levels in wild type mg DN1 thymocytes.
doi:10.1371/journal.pone.0032944.g008
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normal thymocytes, it implies that Notch plays a role in
stimulating the transcription from the alternative promoter.
Mutations in the Notch1 coding sequences are frequently found
in Id1 tumors. Combining the incidences found in either HD or
PEST regions or both, the mutation rate is 66% although the
majorityofthemutationsoccurredinthe PEST domain.Ithasbeen
shown that mutations in the HD domain have a stronger oncogenic
effect than those in the PEST domain when the mutant proteins are
expressed in bone marrow progenitors [25]. Specifically, a PEST
domain mutant, N1DP, was not able to induce T-ALL by itself in
recipient mice transplanted with N1DP-expressing bone marrow
cells but cooperated with an activated K-ras oncogene in
leukemogenesis. Therefore, these mutations may contribute to the
overall Notch activity in Id1 tumors by stabilizing the proteins or
potentiating activation by proteases [44], even though these
mutations may be insufficient to induce T-ALL alone. In light of
the recent discovery of cryptic transcription of the Notch1 gene,
PEST domain mutations could synergize with cryptic transcripts to
boost Notch activity. However, our data presented here could not
ascertain if the mutation resides in the cryptic transcripts.
Regardless, stabilizationof Notch1 would addto the overall activity.
Comparison of the aberrant transcriptional events and muta-
tions in the Notch1 sequence between Id1 and N1C-expressing
tumors reveals that natural selection takes place for gain of Notch
function during tumorigenesis in Id1 transgenic mice. In contrast,
such a selection is not necessary for N1C-expressing tumors as
Notch signaling is already extremely high in the mice, which
develop lymphoma at a much higher rate. Although N1C tumors
produce abundant E1a-containing transcripts, N1C tumors do not
exhibit any intragenic transcriptional initiation. Likewise, no
PEST domain mutations were found in the coding sequences of
these tumors. Consistent with this notion, varying levels of Notch
receptor expression and Notch activities were detected in different
Id1 tumors. Judging from the levels of Notch target gene
expression, some Id1 tumors have Notch activities as high as the
N1C-expressing tumors whereas others have minimal Notch
function. It is also worth noting that expression levels of different
Notch target genes are not uniform in each Id1 tumor or among
all samples. Although Id1 transgenic mice consistently develop
large thymic lymphomas, the addiction to diverse aspects of Notch
activity varied significantly depending on the existence of other
genetic or epigenetic alterations in each tumor. This is consistent
with our previous finding that expression of Hes1 was able to
dramatically potentiate tumorigenesis in Id1 transgenic mice [15].
Our study shows that Notch activities are clearly advantageous
for lymphomagenesis in Id1 transgenic mice, probably through
enhanced survival and/or proliferation of tumor cells. However,
the onset of T cell lymphoma or tumor-free survival of Id1
transgenic mice does not appear to be proportional to the levels of
Notch activities or depend on Notch activation. As shown in
Fig. 10, sample IT1-4 had no mutations in the Notch1 gene or
aberrant Notch1 transcription. Yet, mice with these tumors
succumb to T cell lymphoma faster than the 4 mice with the
highest Notch activities in their tumors (IT20-23). The same also
holds true for the tumors in Group B, which had a wide range of
survival rate. This suggests that inhibition of E2A function by Id1
remains to be instrumental for T cell lymphomagenesis. The fact
that 21 out of 23 tumors maintained very high levels of transgene
expression in Id1 tumors supports such a notion. Furthermore, two
separate studies showed that about 25% of TAL1-expressing
tumors also lack Notch1 mutations, suggesting that inhibition of E
proteins remains relevant [38,39]. It has been postulated that pre-
TCR signaling is necessary for T cell lymphomagenesis in TAL1
and/or LMO1 induced oncogenesis [45]. Our previous studies
have provided evidence to suggest that Id1 potentiate pre-TCR
signaling during T cell development [13,43,46]. Alternative
possibilities may be that the developmental defects caused by
E2A deficiency arrest cells at certain stages when the cells are
particularly vulnerable to oncogenic stimulation through a variety
of secondary mutations and that E proteins could also be
important for expression of tumor suppressors. Therefore, Notch
activation is undoubtedly an important factor but is unlikely the
only factor. When considering therapeutic strategies, it is thus not
sufficient to simply target Notch signaling pathways as they are not
the sole initiating force for T-ALL. Clinical studies already
indicate that T-ALL patients harboring Notch mutations have
more favorable prognosis and Notch-target therapy has compli-
cations [21,32], thus underscoring the necessity to look not only
within but also beyond Notch pathways.
Materials and Methods
Mouse models, tumor tissue collection and
characterization
Mice were housed in the Laboratory Animal Resource Center
of the Oklahoma Medical Research Foundation in a specific
pathogen free environment. This project was approved under the
protocol S0147-3 by the Oklahoma Medical Research Foundation
Institutional Animal Care and Use Committee.
Id1 transgenic mice on the FVB/N background were previously
described [12]. To generate ROSA26-N1C mice, the construct was
created by inserting a SalI-SacII fragment containing human N1C
and GFP sequences isolated from a retroviral construct into the
pBigT vector [16,47], from which a PacI-AscI (partial digest)
fragmentwasisolatedandinserted intotheROSA26PAvector[48].
The construct was linearized and electroporated into 129X1/SvJ
embryonic stem cells [49]. ES cells containing properly targeted
Figure 9. Levels of Ikaros expression. Real-time PCR analyses were
performed using the same cDNA samples used for Figures 3–6. The
levels of Ikaros in each pre-tumor or tumor samples were compared to
the average levels in wild type mice obtained from 6 FVB/N (A) and 4
C57BL/6 (B) mice, respectively.
doi:10.1371/journal.pone.0032944.g009
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PCR assays and then injected into C57BL/6 blastocysts. ROSA26-
stop-N1C progenies were backcrossed to C57BL/6 mice for 10
generations. ROSA26-N1C mice were then crossed with lck-Cre
transgenic mice (Jackson laboratory). Lymphoma development was
monitored at least twice a week. Animals showing symptoms of
tumor formation include hunch back, ruffled fur and labored
breathing were sacrificed for tissue collection and analyses. Single
cell suspensions were used for flow cytometry analysis and solid
tumor tissues were frozen for isolation of total RNA later.
Flow Cytometry and cell sorting
Single cell suspensions from tumor tissues were stained with
fluorescent-conjugated antibodies against CD4, CD8 TCRb and
CD25, and analyzed on a BD LSRII flow cytometer using
standard procedures. To delineate DN thymocyte populations,
thymocyte suspensions were stained with lineage specific antibod-
ies for CD8, TCRc/d, B220, Gr1 and CD3. Upon gating on
lineage negative cells, DN populations were further assayed based
on CD44 and CD25 staining. The CD8 immature single positive
(ISP), DP, and CD4 as well as CD8 single positive (CD4SP and
CD8SP) cell populations were isolated based on CD4, CD8 and
TCRb expression after gating out all cells staining with propidium




cells. Cell sorting was performed on a MoFlo (Dako Colorado,
Inc., Fort Collins, CO) using thymocytes from mice of different
genotypes at 3 to 5 weeks of age.
Real time PCR and RT-PCR analyses
Total RNA from sorted T cells and tumor tissues was isolated
using Trizol reagent per manufacturer’s protocol. Total RNA was
then used to synthesize cDNA using M-MLV reverse transcriptase
Figure 10. Summary of Notch activities and Notch activating mutations or alterations in Id1 tumors. Quantitative data from Figures 3, 5,
6 and 9 were color coded manually based on the value of each sample. Five color-coded brackets (red being the highest and gray the lowest as
indicated by the legend) are used to represent the quantities of a given gene by dividing the second highest value with 5 and assigning the color for
each sample according to its level of expression of the gene. The second highest value was used to better represent the all group by eliminating one
outlier. Notch activities are defined by the collective levels of Notch1, Hes1, Deltex1, Notch3 and c-myc shown in color blocks without borders.
Cryptic transcription of Notch1 was quantified by the level of E1a transcripts and the ratio between 39 and 59 Notch1 transcriptions. The color codes
for the level of Ikaros were inverted such as red means the lowest and gray shows the highest. The nature of the point mutations in the HD and PEST
domains of the Notch1 gene found in Id1 tumors were listed as FS (frame-shift), NS (nonsense) and MS (missense). The phenotypes of the tumors are
shown as CD4 and CD8 double negative (DN), double positive (DP) and single positive (SP).
doi:10.1371/journal.pone.0032944.g010
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using Power SYBR Green PCR Master Mix (Applied Biosystem,
Foster City, CA) on an Applied Biosystems 7500 Real Time PCR
and software analysis system. Levels of transcripts were normalized
against that of b-actin by calculating DCT. Expression levels
relative to that of the reference sample were determined by using
the 2
2DDCT formula. The primers used are b actin F,
GGCTGTATTCCCCTCCATCG, b actin R, CCAGTTGG-
TAACAATGCCATGT; Notch1 59 F, TGTGGACGGCGT-
GAATACCT, Notch1 59 R, GGGCATGAGCTGACATTCGT;
Notch1 39 F, CTGAAGAACGGAGCCAACAA, Notch1 39 R,
CAGCAACACTTTGGCAGTCTCA; Notch1 E1a F, GACCC-
CATTGCTCTCCTTGG , Notch1 E1a R, TGATGGACCTG-
GAAGGGAAGA; Notch1 E1c F, AATGGAGGGAGGTGC-
GAAGT, Notch1 E1c R, GATTGGAGTCCTGGCATCGT;
Hes1 F, CCAGCCAGTGTCAACACGA, Hes1 R, AATGC-
CGGGAGCTATCTTTCT; c-myc F, CACCACCAGCAGC-
GACTCT, c-myc R, TCCACAGACACCACATCAATTTCT;
Deltex1 F, AGGATGTGGTTCGGAGGTACAT, Deltex1 R,
CGCTCCATGCAAATGGTACA; Notch3 F, ATGCCCAG-
GGTGTCTTCCA, Notch3 R, GCAGTAGAGCCATCTGC-
CATTC; total Id1 F, AGGTGAACGTCCTGCTCTAC, total
Id1 R, GTCCCGACTTCAGACTCCG; human Notch1 F,
TGTCTGCCGACGCACAA, human Notch1 R, CGTCGT-
GCCATCATGCAT; Ikzf1 F, AGGGTCAAGACATGTCC-
CAAGT, and Ikzf1 R, CCCCTTCATCTGGAGTGTCACT.
For detection of exon 27b-containing transcript, RT-PCR was
carried out under the following conditions: 94uC for 3 minutes,
followed by 38 cycles of 94uC for 30 seconds, 57uC for 30 seconds
and 72uC for 45 seconds, and a final step of 72uC for 7 minutes.
The primers are exon 27b, CTCTTCAGGGATGGGTTCAT
and exon 33, TGTTCTGCATGTCCTTGTTG as previously
described [26]. PCR products of b-actin, which served as cDNA
quality controls, were generated with the following primers,
GATGGTGGGAATGGGTCAGAAGGACTC, and GAGGT-
CTTTACGGATGTCAACGT CACA.
Sequence analysis of the Notch1 allele
The HD domain and PEST domain of the Notch1 gene were
amplified from cDNA synthesized from individual tumors with the
following primers: GTGATGGCCACTGCGACCAGGGCTG-
TAAC and CGACTGAGTCCTCGCCGAGGGGCTCT, G-
TGGCTTCCCCGGCTCCAGAATG and GAAGCTGGGGT-
CCTGCATCCCACATC. The resulting PCR products were
purified with DNA Gel Extraction Kit (Millipore, Billerica, MA),
and then were analyzed by DNA sequencing.
Statistical analysis
The statistical significance of the difference in gene expression
levels between different sample groups was judged by unpaired t
test. The correlation between different genes expressed in the same
sample was determined by performing Pearson tests using the
Prism 5 software.
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